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HIFSince its discovery as a low-afﬁnity adenosine receptor (AR), theA2B receptor (A2BAR),hasproven enigmatic in its
function. The previous discovery of the A2AAR, which sharesmany similarities with the A2BAR but demonstrates
signiﬁcantly greater afﬁnity for its endogenous ligand, led to the original perception that the A2BAR was not of
substantial physiologic relevance. In addition, lack of speciﬁc pharmacological agents targeting theA2BARmade its
initial characterization challenging. However, the importance of this receptor was reconsidered when it was
observed that the A2BAR is highly transcriptionally regulated by factors implicated in inﬂammatory hypoxia.
Moreover, the notion that during ischemia or inﬂammation extracellular adenosine is dramatically elevated to
levels sufﬁcient for A2BAR activation, indicated that A2BAR signaling may be important to dampen inﬂammation
particularly during tissue hypoxia. In addition, the recent advent of techniques for murine genetic manipulation
alongwithdevelopmentofpharmacological agentswith enhancedA2BAR speciﬁcityhasprovided invaluable tools
for focused studieson the explicit role of A2BAR signaling indifferentdiseasemodels. Currently, studies performed
with combined genetic and pharmacological approaches have demonstrated that A2BAR signaling plays a tissue
protective role in many models of acute diseases e.g. myocardial ischemia, or acute lung injury. These studies
indicate that the A2BAR is expressed on awide variety of cell types and exerts tissue/cell speciﬁc effects. This is an
important consideration for future studieswhere tissue or cell type speciﬁc targeting of the A2BARmay be used as
therapeutic approach. This article is part of a Special Issue entitled: “Adenosine Receptors”.osine Receptors”.
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Fig. 1. A2BAR receptor signal transduction. Coupling of the A2BAR to Gs proteins results
in cAMP upregulation and downstream PKA activation. Signaling through the Gq
receptor leads to elevations in intracellular Ca2+ levels and an increase in PKC.
1330 C.M. Aherne et al. / Biochimica et Biophysica Acta 1808 (2011) 1329–1339Since the initial demonstration that purines have prominent effects
on cardiac function, the endogenous nucleoside adenosine has been
considered a biologically active extracellular signaling molecule [1–9].
The dose–response effects observed with adenosine and synthetic
adenosine analogues [10] in conjunction with the competitive antag-
onism by methylxanthines of adenosine's biological effects supported
the idea of speciﬁc adenosine receptors [2,11,12]. Categorization of
‘purinergic’ receptors into adenosine activated ‘P1-purinoreceptors’ and
nucleotide activated ‘P2-purinoreceptors’ was formally recognized by
Burnstock in 1978 [13]. Based on their ability to inhibit or stimulate
adenyl cyclase, adenosine receptors were subdivided into A1 and A2
subtypes, respectively [14,15]. The discovery of the existence of both
high and low-afﬁnity receptors that activated adenyl cyclase prompted
further divisionof theA2subtype [16,17]. Thehigh-afﬁnity receptorwas
designated the A2A adenosine receptor (A2AAR) and the low afﬁnity,
the A2B adenosine receptor (A2BAR) [18]. All adenosine receptorswere
originally cloned from a canine thyroid library [19] and the A2BAR was
subsequently cloned from the rat hypothalamus [20,21], human
hippocampus [22] and mouse mast cells [23]. Receptor homology
between rat andmouseA2BAR is 96%,while the receptor shares 86%and
87% homology with the human receptor, respectively [21–23]. The
human A2BAR is located on chromosome 17p11.2–p12 and contains a
single intron that interrupts the coding region [24].
Elucidation of the functional role of the A2BAR was hampered by
the lack of pharmacological agents with high speciﬁcity for the A2BAR
[17,18,25–29]. This coupled with the fact that the A2BAR is often co-
expressed with the pharmacologically similar A2AAR in many cell/
tissue types led to the perception that A2BAR may not play an equally
important biological role [27]. More recently, the notion that both
adenosine levels [6,7,9,30–42] and A2BAR expression are dramatically
induced in pathological conditions such as hypoxia or inﬂammation
[7,30,33,34,43–54] gave new consideration to a role for the A2BAR
under such conditions. In fact, several recent studies indicate a tissue
protective role of the A2BAR in dampening hypoxia-induced
inﬂammation and in promoting tissue adaptation to hypoxia
[7,9,47,48,50,52,53,55–57].
1. Expression, regulation and signal transduction via the A2BAR
1.1. Cell and tissue expression pattern
Cloning of the A2BAR and the advent of RT-PCR facilitated speciﬁc
determination of the expression pattern of the A2BAR [20]. Studies of
isolated cultures and whole organs have demonstrated A2BAR
expression in mast cells [23,58], macrophages [59], lymphocytes
[50,60], neutrophils [9,61], dendritic cells [62,63], endothelial cells
[7,9,48,50,64], myocardial cells [30,52,65], retinal epithelium [66],
intestinal epithelium [47,54,67] and pulmonary epithelia [49,53],
particularly on alveolar type II epithelial cells [68]. The original
transcriptional analysis has been supported by the recent creation of a
mouse model with targeted replacement of A2BAR exon 1 with a
reporter gene allowing for speciﬁc elucidation of A2BAR expres-
sion [69]. In this mouse model, A2BAR is expressed in the brain,
spleen, lung, colon, heart and kidney, where it is primarily localized to
the vasculature [20,51,69]. The receptor is highly responsive to many
biological processes and mediators, which induce its expression on a
transcriptional [7,48] or post-translational level [49].
1.2. Transcriptional regulation of A2BAR in hypoxia
The low oxygen tension (hypoxia) present in cells and tissues
under many disease states causes stabilization of the transcription
factor hypoxia-inducible factor (HIF). Transcriptional induction by HIF
occurs following binding of HIF to a consensus sequence known as the
hypoxia responsive element (HRE) on its target gene. The functional
HIF protein consists of a heterodimer of the α and β subunits whichtranslocate to the nucleus following stimulation and activate speciﬁc
target genes [70]. A recent study utilizing human A2BAR promoter
constructs, site-directed mutagenesis and chromatin immunoprecip-
itation, demonstrated functional binding of HIF to a HRE site on the
promoter resulting in increased A2BAR mRNA and protein [48].
Recent analysis has identiﬁed two other putative HRE binding sites on
the human A2BAR promoter and one in the mouse promoter identical
to the functionally conﬁrmed site on the human promoter (Fig. 1)
[48,71]. To date, HIF is the only functionally validated transcription
factor for the A2BAR.
1.3. Novel A2BAR transcriptional regulators
The presence of putative binding sites for a number of transcrip-
tion factors on the mouse and human A2BAR promoter has recently
been described [71]. These include a putative site for NFκB on the
human promoter — an important transcription factor in mediating
inﬂammation, a process with which the A2BAR has been intimately
linked [71]. Intriguingly, the human promoter contains a putative
cAMP response element (CRE), which may implicate adenosine acting
in an autoregulatory manner through upregulation of its second
messenger cAMP [71]. Finally, analysis in this study suggests that
there is an Nkx2.5 binding site in both the human and mouse A2BAR
promoters [71]. This transcription factor is expressed in the
developing heart where it regulates genes associated with cardiac
development [72]. Furthermore, it has been implicated in protecting
the heart from stress signals and maintaining a highly differentiated
cardiac phenotype [73]. Since the A2BAR has been shown to play a
protective role in cardiac disease [30,52,74] it is tempting to speculate
that regulation of A2BAR expression by Nkx2.5 may be of physiolog-
ical and/or pathophysiological relevance [30]. Overall, characteriza-
tion of these novel transcription factor binding sites in the A2BAR
promoter [71] points towards novel pathways by which A2BAR
expression and/or function could be modulated.
1.4. Inﬂammation regulates A2BAR transcription
Multiple mediators associated with inﬂammation have been
demonstrated to increase A2BAR expression. Bacterial lipopolysac-
charide increases A2BAR mRNA expression in macrophages [75]. The
Fig. 2. Putative transcription factor binding sites in the human A2BAR promoter. 1
(TGAAGTG) is the proposed binding site for Nkx2.5, 2 (GCGTG), 3 (CACGC) and 4
(CACGT) are HIF-binding sites. 4 has been conﬁrmed as an HRE bound by HIF-1 in
hypoxia. 5 depicts the CRE binding site (CGTCA).
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numerous cell types, both in vitro and in vivo [75–78]. It has been
proposed that in vascular smooth muscle cells a TNF-α mediated
increase in NAD (P) H oxidase enzymes is responsible for the
upregulation of A2BAR expression [76]. In line with these studies,
the pro-inﬂammatory cytokine, IL-1β, induced A2BAR transcription in
endothelial cells [78]. Finally, IFN-γ was demonstrated to increase
A2BAR mRNA expression in macrophages, which went hand in hand
with increased cell surface expression of the receptor [59]. Interest-
ingly, IFN-γ treatment of intestinal epithelial cells did not alter cell
surface expression of the A2BAR [79]. This suggests that A2BAR
receptor regulation by inﬂammatory mediators is likely to be cell type
speciﬁc.
A recent study showed a novel mechanism for regulation of A2BAR
transcript during inﬂammation [49]. Apanel of inﬂammatorymediators,
including PGE2, IL-1β, IL-6 and IL-4 induces A2BARmRNA in endothelial
and pulmonary epithelial cells [49]. This was not associated with an
increase in transcription but rather with stabilization of mRNA by these
mediators pointing to a post-transcriptional regulation of A2BAR during
inﬂammation [49]. In support of these observations a novel mechanism
for regulation of A2BAR expression by TNF-α in intestinal epithelial cells
has been proposed [80]. Potential binding sites for microRNA (miRNA)
miR27b and miR128a in the 3 untranslated region of A2BAR have been
identiﬁed [80]. Functional analysis demonstrated that both of these
miRNAs can regulate A2BAR expression therefore pointing to a novel
mechanism by which A2BAR expression can be regulated [80].
1.5. A2BAR sub-cellular localization
While initial analysis focused on cellular expression levels of the
A2BAR, a number of studies have analyzed the cell surface expression
of the A2BAR due to the importance of the sub-cellular localization of
the receptor in its function [59,77,81]. Functional signaling through
the receptor to its second messengers occurs when the receptor is at
the cell surface [77,81]. In this regard adenosine itself has been
demonstrated to regulate A2BAR cell surface expression [77,81]. In
intestinal epithelial cells, A2BAR is located intracellularly at rest, and
stimulation of basolateral or apical A2BAR receptors with adenosine
can induce recruitment of the receptor to the apical cell surface
[77,81]. Once at the plasma membrane, the receptor can interact with
a larger complex of scaffolding proteins which may anchor and
stabilize the protein at the cell membrane [81,82]. Furthermore, TNF-
α potentiates the adenosine induced recruitment of the A2BAR to the
plasma membrane in intestinal epithelial cells [77]. These studies
demonstrate that adenosine signaling can be autoregulatory and that
inﬂammatory mediators can potentiate this regulation in terms of
A2BAR cell surface expression.
1.6. Ligand binding and signal transduction
The A2BAR has low afﬁnity for its endogenous ligand, adenosine,
with an EC50 of 24 μM [83]. However, it shows a preference for
adenosine derivatives, with NECA (5′-N-Ethylcarboxamidoadenosine)
being the most commonly utilized and potent A2BAR agonist, with an
EC50of approximately2 μM[26–28]. The lackof speciﬁcA2BARagonists
has posed a particular problem in elucidating the speciﬁc function of the
A2BARwhen the A2AAR is also present [25,27,83]. Rational drug design
using the structure of the receptor has been proposed as a mechanism
for the development of more speciﬁc pharmacological agents [84–86].
The proposed structure of the A2BAR is typical of that of other G-protein
coupled receptors (GPCR), with seven transmembrane (TM 1–7)
domains composed of hydrophobic amino acids connected by three
extracellular and three hydrophilic intracellular loops, bordered by an
extracellular N-terminus and an intracellular C-terminus [21–23]. The
highest homology between the A2BAR and the other adenosine
receptors exists in the TM domains. Since the crystal structure of theﬁrst GPCR, bovine rhodopsin [87] was solved, many recent studies have
worked on homology modeling using the known structure of this
receptor tomodel the adenosine receptors [84–86]. The development of
these models provided an exciting opportunity for rational drug design
to target speciﬁc adenosine receptors. Combining these molecular
models with known sequence data has prompted site-directed
mutagenesis studies of the A2BAR to investigate speciﬁc receptor
components involved in agonist and antagonist recognition. These
studies have implicated amino acids in transmembrane region 3, 5, 6
and 7 in receptor recognition of agonists and antagonists [88,89].
However, to date mutagenesis studies of the A2BAR have revealed
alterations in constitutive activity of the receptor but not in ligand
binding activity [89]. The most recent study proposed a homology
model of the A2BAR which was validated with known A2BAR agonists
and antagonists [86]. This provides an important new tool for the
development of more speciﬁc A2BAR pharmacological agents.
Presently, a novel compound (BAY-60-6583) has been developed
with improved pharmacologic speciﬁcity for the A2BAR [30]. A more
potent A2BAR antagonist is also available [90]. Both will be discussed
in relation to therapeutic efﬁcacy (3).
Upon ligand activation, the A2BAR can activate a number of signal
transduction pathways to mediate its effects. Original studies in all cell
types demonstrated that A2BAR couples to Gs to activate adenyl cyclase
and increase intracellular cAMP levels (reviewed by Feoktistov and
Biaggioni; Fig. 2) [91]. More recently it was shown that the A2BAR can
couple to the Gq family of G-proteins to activate phospholipase C (PLC)
and increase intracellular calcium (Fig. 2) [92,93]. It appears the G
protein coupling of the receptor is cell type dependent and coupling to
Gs results in an anti-inﬂammatory response while coupling to Gq could
potentially results in a pro-inﬂammatory response [94]. Finally, the
A2BAR is the only adenosine receptor subtype that can activate ERK1/2,
JNK and p38 map kinase signaling [29,95–97]. There is an ongoing
debate whether this is mediated through Gq or Gs coupling of the
receptor. A2BAR speciﬁc signaling pathwayswill be further discussed in
relation to speciﬁc disease pathologies (3).
2. A2BAR: physiologic and pathophysiologic function
Initial identiﬁcation of the A2BAR as a low-afﬁnity receptor for its
endogenous ligand resulted in the A2BAR being considered less
physiologically relevant that the high-afﬁnity A2AAR [16,17,26]. The
observation that receptor expression is dramatically enhanced in
situations of low oxygen tension and inﬂammation (2.2, 2.4) coupled
with the dramatic (100-fold) increase in extracellular adenosine
levels under conditions of limited oxygen availability [98,99] point to
a particular role for A2BAR during pathophysiological conditions. In
addition, the alternate signaling pathways to which A2BAR can couple
points to a potentially important role for A2BAR signaling distinct
from that of the A2AAR (2.6, Fig. 2) [29,95–97].
2.1. A2BAR in vascular tone and vascular disease
The earliest observations on the physiological effects of adenosine
point to a vaso-dilatory role for this nucleoside [3]. Initial studies
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effect of A2A speciﬁc agonists or other adenosine receptor antagonists
in certain incidences revealed a contribution of the A2BAR receptor
[100–102]. A2BAR expression has been detected in vascular endo-
thelium and smooth muscle cells where it has been implicated in the
regulation of vascular tone through receptor-mediated vaso-dilatory
effects [100,101,103]. More speciﬁcally, A2BAR activation can inhibit
vascular smooth muscle cell growth and induce endothelial cell
growth [104–106]. Recent characterization of an A2BAR knockout
reporter mouse (A2BAR-KO) supported the expression of the A2BAR
in vascular cell types [69]. These mice do not display an obvious
phenotype but at baseline they demonstrate a mild increase in pro-
inﬂammatory cytokines and upregulation of adhesion molecules on
the vasculature which is associated with IκB downregulation [69].
Furthermore, increased rolling of leukocytes and adhesion to vessel
walls was observed in A2BAR-KOmice. These observations point to an
important role for the A2BAR in attenuation of inﬂammation and
maintenance of vascular tone.
Injury to the vasculature accompanied by accumulation of active
inﬂammatory cells at the site of injury is important initiating events in
vascular pathogenesis [69,107]. In a model of LPS acute inﬂammation
and wire-induced vascular lesion, a signiﬁcant increase in pro-in-
ﬂammatory cytokines was observed in A2BAR-KOmice [69,107]. Bone
marrow chimera experiments demonstrated that A2BAR expression
on bone marrow derived cells contributed signiﬁcantly to protection
from vascular injury as measured by, cytokine levels, adhesion
molecule expression and neointima formation [69,107]. This suggests
that in certain vascular diseases A2BAR expression on hematopoietic
cells can play a tissue protective role.
Novel evidence for a previously unappreciated protective role for the
A2BAR in vascular diseasewas provided by a recent study using A2BAR-
KO reporter mouse [108]. Historically, the inhibition of platelet
aggregation by adenosine was attributed to signaling through the
A2AAR [109–111]. However, it was recently shown that A2BAR
expression is induced in murine platelets during response to stress
and that A2BAR is expressed in human platelets [108,112]. A2BAR
signaling enhanced cAMP which was responsible for inhibition of
platelet aggregation [108]. Genetic loss of A2BAR resulted in increased
platelet aggregation that was associated with changes in pro-aggrega-
tory receptors in platelets. Taken together, this study suggests that the
A2BAR plays a dual role in inhibition of platelet activation in vivo. The
beneﬁcial effect of A2BAR signaling in models of vascular injury and
vascular cells points to a tissue protective role for A2BAR in diseases
affecting the vasculature, such as atherosclerosis.
2.2. A2BAR in modulating inﬂammatory cell functions during hypoxia
(leukomodulation)
Hypoxia is a well-documented inﬂammatory stimulus and results
in tissue polymorphonuclear leukocyte (PMN) accumulation
[5,56,113]. Likewise, increased tissue adenosine levels are commonly
associated with hypoxia [5], and given the anti-inﬂammatory
properties of adenosine, a study utilizing pharmacological and genetic
approaches pursued the hypothesis that adenosine production via
adenine nucleotide metabolism at the vascular surface triggers an
endogenous anti-inﬂammatory response during hypoxia [9]. Initial in
vitro studies indicated that endogenously generated adenosine,
through activation of PMN A2BARs, functions as an antiadhesive
signal for PMN binding to microvascular endothelia. Intravascular
nucleotides released by inﬂammatory cells undergo phosphohydro-
lysis via hypoxia-induced CD39 ectoapyrase (CD39 converts adeno-
sine triphosphate/adenosine diphosphate [ATP/ADP] to adenosine
monophosphate [AMP]) and CD73 ecto-5′-nucleotidase (CD73 con-
verts AMP to adenosine). Extensions of these in vitro ﬁndings using
cd39- and cd73-null animals revealed that extracellular adenosine
produced through adenine nucleotide metabolism during hypoxia is apotent anti-inﬂammatory signal for PMNs in vivo [9,35,113]. More-
over, a more recent study conﬁrmed that A2BAR−/− mice experience
increased inﬂammatory cell accumulation in hypoxic tissues, and that
this phenotype can be resuscitated utilizing an A2BAR agonist (BAY-
60-6583) [50]. Along the same lines, a third study implicated
alternative mechanisms of adenosine receptor stimulation (via the
neuronal guidance molecule netrin-1) in dampening inﬂammatory
cell accumulation during hypoxia [57].Taken together, these ﬁndings
indicate A2BAR signaling in dampening hypoxia-driven accumulation
of inﬂammatory cells – particularly PMN – in inﬂamed or hypoxia
tissues and suggest A2BAR signaling events in “leukomodulation”.2.3. A2BAR in hypoxia, ischemia and ischemic pre-conditioning
Early evidence demonstrated that tissue hypoxia and ischemia
signiﬁcantly increase levels of extracellular adenosine [98,99,114–
119]. Of the four adenosine receptors, the A2BAR is selectively
upregulated during hypoxia [7,48]. Initial in vitro studies implicated
hypoxia-dependent A2BAR expression in maintaining endothelial
barrier function and an angiogenic phenotype [7,48]. The develop-
ment of A2BAR deﬁcient mice allowed for conﬁrmation of this
phenotype in vivo. A2BAR deﬁcient mice or mice treated with an
A2BAR speciﬁc antagonist experienced profound increases in vascular
permeability upon hypoxia exposure [50]. In addition, A2BAR
deﬁcient mice experience increased hypoxia-induced neutrophil
inﬁltration [50]. Importantly, a novel agonist with high speciﬁcity
for the A2BAR (BAY-60-6583) was capable of attenuating hypoxia-
induced permeability changes in vitro and in vivo [50]. Bone marrow
chimeric studies pointed to a speciﬁc role for vascular A2B signaling in
control of hypoxia-induced vascular leakage, while hematopoietic
A2BAR was implicated in the regulation of hypoxia-associated
neutrophil inﬁltration [50]. This indicates that A2BAR signaling on
distinct cell types is protective in hypoxia-associated inﬂammation.
Ischemic pre-conditioning (IP) is an experimental approach in
which exposure to repeated periods of vascular occlusion prior to an
extended ischemic event provides dramatic protection from ischemic
injury [120]. IP in both the heart and kidney is associated with
dramatic increases in adenosine levels [30,121]. Given the tissue
protective responses associated with adenosine it has been hypoth-
esized that the protection provided by IP is related to modulation of
adenosine levels [30,121]. To this end, the role of extracellular
adenosine generation and the adenosine receptors in IP of the heart
and kidney has recently been investigated [30,55,121]. IP in both
organs speciﬁcally induces A2BAR expression, while mice with
speciﬁc deletion of the A2BAR did not experience the protective
effects of IP on the heart or lung [30,55,121]. Replacing IP with treat-
ment using a novel A2BAR agonist (BAY-60-6583) prior to ischemia
protected both organs from ischemia induced injury [30,121].
Furthermore, renal IP was associated with increased A2BAR expres-
sion on the renal vasculature [121]. Bone marrow chimeric studies
revealed that A2BAR expression on the renal vasculature was
responsible for protection of the kidney during IP, as measured by
glomerular ﬁltration and histology [121]. In line with these studies,
expression of the A2BAR was speciﬁcally induced during intestinal
ischemia/reperfusion (IR) injury, while speciﬁc A2BAR agonist and
antagonist treatment revealed that targeting the A2BAR could be used
therapeutically to attenuate intestinal inﬂammation, permeability and
injury associated with gastrointestinal IR injury [47].
The availability of mice with genetic loss of the A2BAR allowed for
development of the initial in vitro observations of a role for A2BAR
during situations of low oxygen tension (hypoxia). In vivo studies
using these mice in models of ischemia have demonstrated that
A2BAR signaling on both hematopoietic and non-hematopoietic cell
types play a protective role during the ischemic disease process.
Importantly, the success of the novel A2BAR agonist, BAY-60-6583, in
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the use of A2BAR agonist therapy in ischemic disease.
The mechanism by which A2BAR signaling mediates tissue protec-
tion in models of ischemia and ischemia-associated inﬂammation has
been investigated in an innovative study [122]. The authors demon-
strated that adenosine is released by hypoxic preconditioned cells in a
similar fashion to tissues exposed to ischemic pre-conditioning [122].
Adenosine signaling predominantly through the A2BAR set off a
signaling cascade whereby the E3 ubiquitin ligase, cullin-1, was
deneddylated rendering it incapable of ubiquitinating IκB-α and
suppressing NFκB activity [122]. This is a novel and innovative ﬁnding
whichmay point to the anti-inﬂammatory pathway responsible for the
protective responses of A2BAR signaling during ischemic injury.
Over the last 10 years, there have been reports that the neuronal
guidance molecule netrin-1 binds to the A2BAR and modulates
signaling through the receptor [57,123]. Netrin-1 is induced at
mucosal surfaces by hypoxia [57]. Intriguingly, netrin-1 signaling
through the A2BAR on hematopoietic cells can inhibit hypoxia-
induced inﬂammatory cell inﬁltration into mucosal organs [57].
Therefore, conventional A2BAR agonist signaling or alternative
A2BAR signaling molecules could be a basis for future therapeutic
strategies in ischemic disease.
2.4. A2BAR in acute kidney injury (AKI)
AKI is a devastating disease of the kidneys, that has previously
been referred to as acute kidney renal failure. It is deﬁned as a
decrease in the glomerular ﬁltration rate (GFR), occurring over a
period of minutes to days. AKI is frequently caused by renal ischemia,
and represents an important cause of morbidity and mortality of
hospitalized patients [124–126]. A recent study of hospitalized
patients revealed that only a mild increase in the serum creatinine
level (0.3 mg/dl) is associated with a 70% greater risk of death than in
persons without any increase [125,126]. Therapeutic approaches are
very limited and themajority of interventional trials in AKI have failed
in humans [127]. Therefore, additional therapeutic modalities to
prevent AKI are urgently needed.
Several studies utilizing a model of isolated renal artery occlusion
[128] to induce ischemic AKI have indicated a protective role of
extracellular adenosine generation by dampening kidney inﬂamma-
tion and improving organ function [36,129]. Based on these ﬁndings,
several studies pursued a kidney-protective role for extracellular
adenosine signaling during ischemia, including studies on the A1AR
[1,2,130], or the A2AAR [131,132]. A recent study by Grenz et al.
attempted to compare adaptive responses elicited by IP treatment of
the kidneys in all four adenosine receptor deﬁcient mice. These
studies determined a selective role for the A2BAR for IP-dependent
kidney protection [51]. Moreover the authors could re-capitulate an
A2BAR−/− phenotype by pre-treatment with an A2BAR antagonist
(PSB1115). Finally, studies utilizing an A2BAR agonist (BAY-60-6583)
were associated with robust protection from AKI in wild-type, and
essentially no effect in A2BAR−/− mice. Studies utilizing a transgenic
A2BAR reporter mouse [69,107], in conjunction with functional
experiments in A2BAR bone marrow chimera indicate that A2BAR-
dependent kidney protection involves vascular A2BAR signaling
events [51]. However, these studies will require conﬁrmation on a
tissue-speciﬁc level, e.g. by utilizing the Cre-lox system to conﬁrm
that adenosine-A2BAR-dependent kidney protection from AKI in-
volves vascular A2BARs.
2.5. A2BAR in acute lung injury
Acute lung injury (ALI) is a syndrome characterized by acute
hypoxemic respiratory failure in the setting of non-cardiogenic
pulmonary edema [133]. The pathogenesis of ALI is characterized by
the inﬂux of a protein-rich edema ﬂuid into the interstitial and intra-alveolar spaces as a consequence of increased permeability of the
capillary-alveolar barrier [133]. Molecular aspects of how capillary-
alveolar leakage is caused and maintained during ALI remain
unknown, and studies linking its mechanisms with mechanical
ventilation or mechanical stretch are areas of intense investigation
[117,134–136]. Initial studies using a murine model of ventilator
induced lung injury (VILI) to model ALI in the setting of mechanical
ventilation and stretch demonstrated elevated levels of extracellular
adenosine in the lung [31]. Similarly, an in vitro model of cell stretch
demonstrated the release of adenosine from lung epithelial cells
cultured under stretch conditions [31]. Mice deﬁcient in the enzymes
required for the generation of extracellular adenosine were more
susceptible to capillary-alveolar leakage and lung inﬂammation in the
VILI model [31]. This suggested that extracelluar adenosine and
adenosine receptor signaling pathways are protective in ALI. The
availability of mice with genetic deletion of the individual adenosine
receptors allowed for dissection of the receptor responsible for the
protective effects of adenosine in ALI [136]. Speciﬁc enhancement of
albumin leakage and decrease in survival was observed in A2BARmice
subjected to VILI [136]. This initial ﬁnding demonstrated a speciﬁc role
for the A2BAR in acute lung injury. Previous study had demonstrated
attenuation of pulmonary inﬂammation during hypoxia by A2BAR
signaling [122]. Lung inﬂammation was assessed by neutrophil
accumulation and cytokine levels in the lung as a result of VILI
[136]. Mice deﬁcient in the A2BAR demonstrated dramatic enhance-
ment in pulmonary neutrophil numbers and pro-inﬂammatory
cytokines (TNF-α, IL-6 and KC) following VILI [136]. Interestingly,
levels of anti-inﬂammatory cytokine IL-10 were signiﬁcantly de-
creased in the A2BAR deﬁcient mice [136]. In a support of an anti-
inﬂammatory role for A2BAR signaling in VILI, pulmonary A2BAR
expression was induced during VILI and was associated with cAMP
and PKA activation [136]. The speciﬁc role of the A2BAR in inducing
pulmonary cAMP was conﬁrmed using A2AAR deﬁcient mice [136].
Studies performedwith two distinct A2BAR antagonists conﬁrmed the
observations in A2BAR deﬁcient mice [31,136]. Finally, a novel A2BAR
agonist (BAY-60-6583) improved survival, albumin leakage and
attenuated pulmonary inﬂammation in both VILI and endotoxin
induced ALI [136]. Bone marrow chimeric studies revealed a dual role
for A2BAR during VILI with pulmonary A2BAR attenuating lung edema
and albumin leakage, while both pulmonary and hematopoietic
A2BAR contributed to attenuation of inﬂammation during VILI [136].
The protective effect of A2BAR signaling on capillary-alveolar leakage
is consistent with previous observations of A2BAR-dependent
maintenance of barrier function [50,69,107]. In parallel with the
protective effect of A2BAR on inﬂammatory parameters in VILI,
hematopoietic A2BAR was demonstrated to be essential for hypoxia-
associated neutrophil accumulation [50]. In a complimentary study,
mice were exposed to inhaled LPS to mimic sepsis induced acute lung
injury [49]. A reproducible protective effect of A2BAR signaling in this
model provided further conﬁrmation for a tissue protective role for
A2BAR in acute lung injury [49]. These studies suggest that targeting
of the A2BAR during ALI would be of therapeutic beneﬁt, both in the
setting of improving pulmonary barrier function and inﬂammation
associated mechanical or sepsis induced lung injury.
2.6. Asthma and chronic lung disease
In contrast to the beneﬁcial effects of adenosine-A2BAR signaling
in acute conditions affecting the lung, the role of elevated adenosine
levels in chronic lung pathologies, including asthma and chronic
obstructive pulmonary disease (COPD) is somewhat more controver-
sial [90,137–140]. Original studies identiﬁed elevated levels of
adenosine present in the lungs of asthmatics which correlate with
the degree of the inﬂammatory insult [141,142]. Importantly,
adenosine induces acute bronchoconstriction in asthmatics or COPD
sufferers, but not in normal individuals, pointing to an underlying
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with mice deﬁcient in the enzyme that deaminates adenosine to
inosine – adenosine deaminase (ADA) – have elevated levels of
adenosine present in the lung [145]. The elevated levels of adenosine
in these mice correlate with pulmonary inﬂammation and airway
remodeling symptoms [145]. Studies in ADA-deﬁcient mice [145,146],
mice with partial ADA deﬁciency [147,148] and mice undergoing ADA
replacement therapy [149] demonstrate adenosine-dependent mast-
cell degranulation, increase in number of lung macrophages and
eosinophils, mucous metaplasia, airway enlargement and hyper-
responsiveness. Interestingly, mice that are incapable of extracellular
adenosine generation experience enhanced lung inﬂammation and
ﬁbrosis in a model of lung ﬁbrosis [138]. The paradoxical effects of
adenosine in these studies points to potentially differential effects of
adenosine during chronic lung disease which may be due to the
involvement of different adenosine receptor signaling pathways on
distinct cell types.
Original studies using an adenosine uptake inhibitor implicated cell
surface receptors in adenosine-mediated bronchoconstriction in asth-
matics [150]. Further evidence for speciﬁc adenosine receptor involve-
mentwas illustratedby the efﬁcacy of adenosine receptor antagonists in
adenosine-mediated bronchonstriction [151,152]. Degranulation of
mast cells and subsequentmediator release is an important component
of the bronchoconstriction observed in asthma [153]. Importantly,
investigation of adenosine receptor subtypes on mast cells implicate
A2BAR signaling in degranulation and mediator release [23,58]. A2BAR
induced mediator release from mast cells is facilitated by the Gq
pathway and can be enhanced by Gs signaling [95,154]. In an extension
of these studies, A2BAR signaling has been implicated in increasing
cytokine release from other cell types implicated in asthma, including
airway epithelial cells [155], bronchial smooth muscle cells [156],
macrophages [157] and pulmonary ﬁbroblasts [158].
Identiﬁcation of A2BAR signaling as potential pathway in the
pathogenesis of asthma prompted the investigation of A2BAR
signaling in other chronic conditions affecting the lung, including
COPD and idiopathic pulmonary ﬁbrosis (IPF) [90,139,140,159]. The
receptor is elevated in COPD patients where biopsy staining localized
A2BAR expression to activated macrophages and mast cells [160,161].
Studies of IPF patients have demonstrated that expression of the
receptor is increased in the remodeled airway epithelium and in the
inﬂammatory cells [159,161]. As previously introduced, mice with
partial or complete deﬁciency in the adenosine deaminating enzyme,
ADA, experience adenosine dependant pulmonary ﬁbrosis and have
been proposed as murine models of adenosine dependant lung
ﬁbrosis [148,162]. Analysis of adenosine receptor expression revealed
that ADA-deﬁcient mice have elevated pulmonary expression of
A2BAR [90,148]. Based on original ﬁndings of a protective role for
A2BAR antagonists in the resolution of pulmonary inﬂammation and
ﬁbrotic processes [154,157,158,163], pharmacological antagonism of
the A2BAR was pursued as a therapeutic strategy in ADA-deﬁcient
mice [90]. ADA-deﬁcient mice were treated with a novel A2BAR
antagonist, CVT-6883, which has high-afﬁnity for the A2BAR and is
capable of signiﬁcantly inhibiting agonist induced increases in cAMP
while not affecting alternative A2BAR signaling pathways [90].
Antagonist treatment resulted in decreased inﬂammatory inﬁltration
into the lungs, in parallel with decreased pulmonary levels of pro-
inﬂammatory cytokines TNF-α and IL-6 [90]. Intriguingly, a novel
study with mice genetically deﬁcient in both ADA and A2BAR was
performed to support the hypothesis that A2BAR deﬁciency attenu-
ates chronic pulmonary inﬂammation [139]. However, this study
demonstrated the opposite effect, with the double knockout mice
having a signiﬁcantly decreased survival rate, with enhanced
pulmonary inﬂammation and airway destruction [140]. In particular,
these mice experienced excessive lung neutrophilia with loss of
pulmonary barrier function [140], consistent with previous studies in
a model of acute lung injury [136]. This phenotype may be due toincreased levels of TNF-α in the double knockout mice [140], which
have also been observed in A2BAR deﬁcient mice following LPS
exposure [69]. Mice deﬁcient in A2BAR and ADA have enhanced
airway destruction which was associated with increased damage to
the alveolar airways, airway angiogenesis and collagen production
[140]. The authors suggest that the enhanced lung tissue destruction
may be due to the signiﬁcant accumulation of pulmonary neutrophils
in the double knockout mice [140]. Consistent with pharmacological
studies where treatment of ADA-deﬁcient mice with an A2BAR
antagonist decreased pulmonary levels of IL-6 [90], mice lacking both
ADA and A2BAR had reduced levels of IL-6 in the lung [140]. IL-6 is
generally considered a pro-ﬁbrogenic cytokine and speciﬁc regulation
of pulmonary IL-6 by A2BAR may point to a critical event in the
pathogenic effects of A2BAR involvement in lung ﬁbrosis [140]. The
authors explain the opposing effects observed in their pharmacolog-
ical and genetic study by indicating that A2BAR signaling may be
tissue protective in the acute stage of disease and progress to a
pathogenic response in chronic lung inﬂammation [140]. However,
the role for adenosine and A2BAR signaling in chronic lung disease
remains controversial as mice that lack the enzyme (CD73) to
generate extracellular adenosine experience enhanced pulmonary
inﬂammation and ﬁbrosis in a murine model of bleomycin-induced
lung injury [138]. What is evident is the importance of divergent cell
types in the different models, namely the alveolar macrophage in the
ADA-deﬁcient mice and the neutrophil in the A2BAR/ADA-deﬁcient
mouse indicates the potential for cell type dependent effects of A2BAR
signaling. Taken together it is clear that it will be important to clarify
the effect of speciﬁc targeting of the A2BAR at different time-points or
on different cell types in the chronic disease process to elucidate the
exact therapeutic function of A2BAR signaling.
2.7. A2BAR in intestinal inﬂammation
There is strong evidence to suggest that extracellular adenosine
plays a protective role during intestinal inﬂammation [164–166]. This
prompted investigation of the role for adenosine receptor signaling
during intestinal inﬂammation. Of the four adenosine receptors, the
A2BAR is speciﬁcally expressed in the gastrointestinal tract [67]. Initial
studies focusing on the role of the receptor in vitro demonstrated that
A2BAR is located on both the apical and basolateral surface of the
intestinal epitheliumwhere it can induce chloride secretion through a
cAMP dependent pathway, suggesting that A2BAR could be important
in the diarrheal process [67]. Cell culture studies determined that the
A2BAR associates with adenylate cyclase isoform 6 in intestinal
epithelial cells to mediate A2BAR-dependent increases in intracellular
cAMP [167]. A recent study pointed to the physiological relevance of
A2BAR expression in colonic motility [168]. Observations in mice
lacking the A2BAR or mice treated with an A2BAR antagonist pointed
to a phenotype similar to human constipation, with increased stool
retention and delayed colonic emptying [168]. Electrophysiological
studies demonstrated A2BAR agonists induce colonic relaxation by
increasing levels of nitric oxide [168]. These novel in vivo observations
indicate that speciﬁc targeting of the A2BAR could be used as a
therapeutic approach for diarrhea or constipation.
A2BAR signaling has been implicated in inﬂammatory conditions that
affect the intestine, such as Crohn's disease and ulcerative colitis that
affect the small intestine and colon, respectively [54,77,169,170]. A2BAR
expression is induced during intestinal ischemia reperfusion and by
inﬂammatory mediators closely associated with inﬂammatory bowel
diseases (2.4) [47,77]. As previously discussed, the A2BAR signaling
attenuates intestinal inﬂammation associatedwith ischemia/reperfusion
injury [47]. In parallel with these studies, genetic or pharmacological
inhibition of A2BAR resulted in exacerbation of the acute inﬂammatory
phase of chemically-induced colitis [54]. All parameters measured
demonstrated a greater disease activity in A2BAR deﬁcient mice,
including histological damage and inﬂammatory cell inﬁltration [54].
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in IL-10 expression in mice lacking the A2BAR, indicating a regulatory
role for A2BAR modulation of IL-10, a protective cytokine, in dextran
sodiumsulphate (DSS) induced colitis [54]. This anti-inﬂammatory effect
of A2BAR signaling corresponds with the previously mentioned studies
on intestinal ischemia–reperfusion injury [47], and studies in other
models of ischemia and mucosal inﬂammation [50,57,136].
2.8. Existing controversies
In contrast to several studies indicating a protective role of A2BAR
signaling in intestinal tissue protection and attenuation of inﬂamma-
tion, recent reports demonstrated a deleterious effect of A2BAR
signaling in murine colitis [169,170]. The initial study depicted mice
deﬁcient in A2BAR were protected in models of colitis, linking this
phenotype with a diminished release of the chemoattractant KC from
colonic epithelia and therefore reduced neutrophil inﬁltration in
A2BAR deﬁcient mice, a common component of the pathogenic
response in the models tested [170]. A second study used a novel
speciﬁc A2BAR antagonist to demonstrate that blockade of A2BAR
improves colitis associated disease activity [169]. A2BAR blockade
was associated with attenuation of colitis-induced diarrhea and
inﬂammatory cell inﬁltration [169]. Speciﬁc A2BAR signaling on the
intestinal epithelium or immune cells has yet to be implicated in the
protective effects seen with blockade of A2BAR [169]. Why the results
from these studies differ is not yet fully understood. Potential
explanations for the divergent results studies could include details
in the colitis protocol, disparity in murine strains with genetic
deletion of the A2BAR or differences in the ambience, including
diversity in bacterial ﬂora of the mice. Of particular interest is the use
of the IL-10 knockout model in the study demonstrating protection by
A2BAR blockade [169]. Previous study had linked A2BAR signaling as a
protective response in murine colitis through the regulation of IL-10
expression [54]. Therefore, the lack of IL-10 in this model may explain
the divergent effects observed with A2BAR blockade [54,169].Fig. 3. A2BAR involvement inFurthermore, it seems important to point out that in a related study,
A2BAR deﬁcient mice experienced a pro-inﬂammatory phenotype
with increased susceptibility to Salmonella infection [170]. This is in
agreement with previous tissue protective effects of A2BAR signaling
that have been demonstrated in many models of inﬂammation and
ischemia [30,47,49,50,55,57,69,107,121,136]. Due to the expression of
A2BAR on intestinal epithelia and immune cells, cell types which have
an important interplay in inﬂammatory bowel diseases, it is of
greatest importance to elucidate the cell speciﬁc effects of A2BAR
signaling in regards to inﬂammatory bowel diseases.
3. Conclusion
Elucidation of a low-afﬁnity subtype of the A2 adenosine receptors,
theA2BAR, led to the intriguingpossibility that therewasaphysiological
receptor to counterbalance thehigh-afﬁnityA2AAR [20]. Initial attempts
to characterize the A2BAR were hampered by the lack of speciﬁc
pharmacological agents to target the receptor [15,16,18,26]. The advent
of more sensitive molecular techniques allowed for the detection of the
A2BAR on many cell types, particularly in the vasculature, which gave
initial insight into a functional role for the A2BAR. Geneticmanipulation
techniques have played a key role in recent elucidation of the functions
of the A2BAR. Not only has this technology been used to investigate
A2BAR function, but generation of an A2BAR deﬁcient-reporter mouse
has allowed for highly sensitive detection of A2BAR expression [69]. The
availability of geneticmodels coupledwith novel pharmacological tools
for speciﬁc targeting of the A2BAR has signiﬁcantly advanced our
knowledge of the functional consequences of A2BAR signaling.
Transcriptional studies revealed that A2BAR expression is signiﬁ-
cantly upregulated in response to a variety of inﬂammatory mediators
(2.4). Recent analysis of the A2BAR promoter revealed novel transcrip-
tion factors that may modulate A2BAR expression. Analysis of these
signaling pathways could be an interesting avenue of investigation that
may implicate A2BAR signaling in a previously unappreciated biological
role. The latest studies reveal that inﬂammatory mediators areinﬂammatory disease.
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mechanisms [49,80]. Further investigation of these pathways will yield
novel insight into alternativemethodsof regulation of theA2BARduring
the inﬂammatory disease process.
The observation that A2BAR expression is controlled by hypoxia
and inﬂammation is signiﬁcant when considering that the level of
extracellular adenosine is dramatically enhanced in ischemic and
inﬂamed tissue. This has prompted novel studies to investigate a
potential role for A2BAR signaling in many models of ischemia and
inﬂammation. The availability of mice deﬁcient in the A2BAR and
reporter mice deﬁcient in the A2BAR has greatly facilitated these
studies. Current reports demonstrate a tissue protective role for
A2BAR signaling during ischemic disease or diseases characterized by
acute inﬂammation. Expression of A2BAR on the hematopoietic cells
is largely agreed to be responsible for the anti-inﬂammatory effect of
A2BAR in these models. Development of an A2BAR speciﬁc agonist,
BAY-60-6583, that has dramatically enhanced afﬁnity for the A2BAR
has provided an important pharmacological tool to elucidate the
outcome of therapeutically targeting the A2BAR [30]. Application of
this novel receptor agonist in vivo has demonstrated profound tissue
protective responses with speciﬁc enhancement of A2BAR signaling in
murine models of acute ischemia and inﬂammation. Both, genetic and
pharmacological observations support the rationale for treatment
with A2BAR agonists in ischemic disease. The role of A2BAR in
diseases characterized by chronic inﬂammation, such as COPD and
inﬂammatory bowel disease, is somewhat more controversial. Studies
have demonstrated both tissue protective and deleterious effects of
A2BAR signaling in models of both diseases. The involvement of
A2BAR signaling on distinct cell types involved in the chronic disease
process has yet to be elucidated (Fig. 3). What can be taken from these
conﬂicting studies is that further investigation of the cell speciﬁc
effect of A2BAR signaling in these models is of the utmost importance.
This would allow for speciﬁc targeting of the A2BAR on the most
appropriate cell types at the relevant point in the disease process
where A2BAR signaling could exert its maximal therapeutic effect.
It is demonstrated by the multiple studies employing the new
genetic and pharmacological tools speciﬁc for the A2BAR that the
A2BAR has signiﬁcantly advanced in biological importance since its
humble beginnings as the low-afﬁnity counterpart to the A2AAR. It is
exciting to think what the future holds for the therapeutic potential of
the A2BAR.
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